Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Michael Hayden Rosenthal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5085-3904; OpenAlex author ID A5031717380; NIH RePORTER profile ID 9712002. Sources: OpenAlex.

Their work

Papers
25 (first author 3, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
128
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 3 papers · 2023: 7 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers, 1 grant

Papers 25

  1. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70573↗
  2. Pancreatic Cancer Screening and Early Detection: Current Strategies and Emerging Innovations in Imaging. Co-author DOI 10.1016/j.rcl.2026.01.005↗
  3. Resistance exercise combined with protein supplementation for skeletal muscle mass in people with pancreatic cancer undergoing neoadjuvant chemotherapy: Study … Co-author DOI 10.1371/journal.pone.0322192↗
  4. Imaging for Early Detection of Pancreatic Ductal Adenocarcinoma: Updates and Challenges in the Implementation of Screening and Surveillance Programs. Co-author DOI 10.2214/ajr.24.31151↗
  5. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  6. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. Co-author DOI 10.1038/s41467-023-38088-2↗
  7. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. First author DOI 10.1038/s41467-023-40024-3↗
  8. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Co-author DOI 10.1038/s41591-023-02332-5↗
  9. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  10. Potential of artificial intelligence in the risk stratification for and early detection of pancreatic cancer. First author DOI 10.20517/ais.2022.38↗
  11. Beyond the AJR: CT Radiomic Features of the Pancreas Predict Development of Pancreatic Cancer. Co-author DOI 10.2214/ajr.22.28582↗
  12. What Can We Learn About Pancreatic Adenocarcinoma from Imaging? Co-author DOI 10.1016/j.hoc.2022.06.003↗
  13. Surveillance Imaging in Individuals at High Risk for Pancreatic Cancer: Not a Ceiling, but Rather a Floor Upon Which to Build. Co-author DOI 10.1053/j.gastro.2021.12.259↗
  14. A Growing Hope for Earlier Detection of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2022.07.080↗
  15. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Co-author DOI 10.1097/mpa.0000000000001762↗
  16. Diabetes, Weight Change, and Pancreatic Cancer Risk. Co-author DOI 10.1001/jamaoncol.2020.2948↗
  17. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08087-z↗
  18. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Ea… Co-author DOI 10.3389/fonc.2020.596931↗
  19. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. First author DOI 10.1158/1055-9965.epi-19-0370↗
  20. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  21. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  22. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Last author DOI 10.1093/annonc/mdx180↗
  23. Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al. Last author DOI 10.1093/annonc/mdx273↗
  24. When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2016.70.2134↗
  25. Imaging and Endoscopic Approaches to Pancreatic Cancer. Co-author DOI 10.1016/j.hoc.2015.04.008↗

Grants 1

  1. Altered metabolism and machine learning for pancreatic cancer early detection U01CA210171↗

Closest collaborators

The 25 strongest of 128 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 17 shared papers, 1 shared grant, 2017–2026 · strength 3.48
  2. Khoschy Schawkat · 5 shared papers, 2022–2026 · strength 1.36
  3. Chen Yuan · 7 shared papers, 2018–2026 · strength 0.89
  4. Jonathan Andrew Nowak · 5 shared papers, 2020–2026 · strength 0.70
  5. Avinash R. Kambadakone · 3 shared papers, 2023–2026 · strength 0.66
  6. Kimmie Ng · 5 shared papers, 2019–2023 · strength 0.57
  7. Matthew B.B. Yurgelun · 3 shared papers, 2022–2023 · strength 0.51
  8. Ana Babić · 5 shared papers, 2018–2023 · strength 0.50
  9. Qiao-Li Wang · 3 shared papers, 2023–2026 · strength 0.49
  10. Thomas E. Clancy · 5 shared papers, 2017–2023 · strength 0.48
  11. Chris Sander · 4 shared papers, 2020–2023 · strength 0.46
  12. Anirban Maitra · 3 shared papers, 2020–2023 · strength 0.43
  13. Peter Kraft · 3 shared papers, 2020–2023 · strength 0.38
  14. Natalia I. Khalaf · 4 shared papers, 2019–2023 · strength 0.37
  15. Kimberly J. Perez · 3 shared papers, 2017–2023 · strength 0.36
  16. Shravya Srinivas Rao · 1 shared paper, 2026 · strength 0.36
  17. Yoshifumi Noda · 1 shared paper, 2026 · strength 0.36
  18. Eugene Jon Koay · 2 shared papers, 2020–2023 · strength 0.35
  19. Andrew J. Aguirre · 3 shared papers, 2020–2023 · strength 0.34
  20. Kunal Jajoo · 2 shared papers, 2015–2022 · strength 0.31
  21. Ott Le · 2 shared papers, 2023–2024 · strength 0.30
  22. Samuel Joseph Galgano · 2 shared papers, 2023–2024 · strength 0.30
  23. Lyndon Luk · 2 shared papers, 2023–2024 · strength 0.30
  24. Erik V. Soloff · 2 shared papers, 2023–2024 · strength 0.30
  25. Naveen M. Kulkarni · 2 shared papers, 2023–2024 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.